GoodLife Pharmacy Revenue and Competitors

Nairobi,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • GoodLife Pharmacy's estimated annual revenue is currently $69.1M per year.(i)
  • GoodLife Pharmacy's estimated revenue per employee is $201,000

Employee Data

  • GoodLife Pharmacy has 344 Employees.(i)
  • GoodLife Pharmacy grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

Goodlife Pharmacy Africa is a fast-growing Pharmacy and health hub and only one of its kind in East Africa with 58 branches in the region. The company provides trusted pharmaceuticals to customers across the population from convenient locations – with a total reach of over 2 million people. Goodlife also offers a range health services including Blood Pressure, Blood Glucose, Body Mass Index, Malaria and Family Nutrition, Doctor Consultations, Laboratory Services in select locations. Co-founded by Dr Josh Ruxin in 2013, with the aim of “Helping the Nation to Look and Feel Good One Person at a Time”, Goodlife focuses on providing high-quality individual customer care at an affordable price and convenient locations across the region. By 2020 Goodlife Pharmacy aims to have over 200 branches in Eastern Africa.

keywords:N/A

N/A

Total Funding

344

Number of Employees

$69.1M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

GoodLife Pharmacy News

2022-04-06 - Leapfrog sells 30pc Goodlife Pharmacy stake

Private Equity firm Leapfrog Investments has sold a 30 percent stake in regional healthcare chain Goodlife Pharmacy to pan African medicine...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$122.9M36410%N/A
#2
$64M39428%$42.7M
#3
$50.6M39714%N/A
#4
N/A4058%N/A
#5
$330.2M75780%$125M